ESH AL 2018 | Advice about ALL treatment in the clinical setting
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment of acute lymphoblastic leukemia (ALL) in clinical practice and in a clinical trial setting, and the issues physicians face in a clinical environment. Prof. Haferlach then provides advice to doctors on what information they should give ALL patients about their condition. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Get great new content delivered to your inboxSign up